Why EyePoint’s Index Additions Matter for Investors

EyePoint (EYPT) has just been added to several Russell growth indices, a change that often prompts passive funds and ETFs to adjust holdings. This can potentially increase trading activity and investor attention around the stock.

For you as an investor, these index inclusions are less about a sudden shift in company fundamentals and more about understanding how benchmark membership can affect liquidity, visibility and who might be buying or selling EyePoint over time.

EyePoint’s recent index additions come after a mixed year in the market, with the share price at $13.98. The 1 month share price return is 11.57%, but the year to date share price has declined by 20.02%, while the 1 year total shareholder return of 43.83% and 5 year total shareholder return of 74.53% point to stronger longer term momentum.

If you are assessing how EyePoint fits alongside other healthcare opportunities, this can be a good moment to broaden your watchlist using our screener for 40 healthcare AI stocks

With EyePoint trading at $13.98 against an analyst price target of $40.00 and a low value score of 2, you have to decide: is this a genuine mispricing, or are markets already assuming a lot of future growth?

Most Popular Narrative: 62.2% Undervalued

Compared with the last close at $13.98, the most followed valuation narrative for EyePoint anchors on a fair value of $37.00, built from detailed forecasts and cash flow assumptions.

Analysts are assuming EyePoint's revenue will grow by 261.6% annually over the next 3 years. Analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from 3567.1% below breakeven to the average AU Pharmaceuticals industry of 19.6% in 3 years.

Want to see how EyePoint gets from heavy losses today to those projected margins and earnings? The narrative walks through aggressive revenue expansion, rising profitability and a rich future earnings multiple that together underpin that $37.00 figure.

Result: Fair Value of $37.00 (UNDERVALUED)

However, this bullish EyePoint story leans heavily on DURAVYU, so any clinical or regulatory setback, or slower than expected adoption in wet AMD and DME, could quickly undermine it.

Another View on EyePoint’s Valuation

The narrative around EyePoint leans heavily on analyst targets and future earnings assumptions, yet the SWS DCF model presents a different picture. At $13.98, EyePoint is shown as trading about 87.7% below an estimated future cash flow value of $113.52. This raises a clear question for you as an investor: is the market too cautious, or is the model too optimistic?

Next Steps

With EyePoint carrying both clear risks and meaningful potential rewards, now is a good time to review the underlying data for yourself and decide what really matters. To see these trade offs set out side by side, take a closer look at the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond EyePoint?

If EyePoint has sharpened your focus, do not stop here, broaden your watchlist now so you are not late to the next opportunity.

• Target resilient returns by scanning companies with lower risk profiles through the 75 resilient stocks with low risk scores.
• Spot potential mispricings early by reviewing companies highlighted in the screener containing 18 high quality undiscovered gems.
• Prioritise financial strength by filtering for companies using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.